A Calmy
Overview
Explore the profile of A Calmy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ariza-Vioque E, Ello F, Andriamamonjisoa H, Machault V, Gonzalez-Martin J, Calvo-Cortes M, et al.
Infect Dis Ther
. 2022 Jun;
11(4):1327-1341.
PMID: 35767219
Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals...
2.
Hovaguimian F, Martin E, Reinacher M, Rasi M, Schmidt A, Bernasconi E, et al.
HIV Med
. 2021 Oct;
23(2):146-158.
PMID: 34605153
Objectives: The aim of the study was to assess the feasibility of a national pre-exposure prophylaxis (PrEP) programme using smartphone-compatible data collection. Methods: This was a multicentre cohort study (NCT03893188)...
3.
Kovari H, Surial B, Tarr P, Cavassini M, Calmy A, Schmid P, et al.
HIV Med
. 2021 Apr;
22(7):623-628.
PMID: 33880839
Objectives: We previously demonstrated an association between tenofovir disoproxil fumarate (TDF) and chronic liver enzyme elevation in the D:A:D study. The objective of the study was to assess changes in...
4.
Metral M, Nadin I, Locatelli I, Tarr P, Calmy A, Kovari H, et al.
HIV Med
. 2019 Dec;
21(5):342-348.
PMID: 31883203
Objectives: Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming neuropsychological assessment. Screening tools are needed to identify when neuropsychological referral is indicated. We examined the positive and negative predictive...
5.
Metral M, Darling K, Locatelli I, Nadin I, Santos G, Brugger P, et al.
HIV Med
. 2019 Oct;
21(1):30-42.
PMID: 31589807
Objectives: The aim of the study was to examine baseline neurocognitive impairment (NCI) prevalence and factors associated with NCI among patients enrolled in the Neurocognitive Assessment in the Metabolic and...
6.
Biver E, Calmy A, Meier C
Osteoporos Int
. 2019 May;
30(8):1707.
PMID: 31143991
No abstract available.
7.
Hachfeld A, Darling K, Calmy A, Ledergerber B, Weber R, Battegay M, et al.
HIV Med
. 2019 May;
20(6):418-423.
PMID: 31062497
Objectives: Late presentation (LP) to HIV care disproportionally affects individuals from sub-Saharan Africa (SSA). We explored the reasons for late presentation to care among this group of patients in the...
8.
Biver E, Calmy A, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari H, Ferrari S, et al.
Osteoporos Int
. 2019 Jan;
30(5):1125-1135.
PMID: 30603840
Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general population. Accordingly, age-related comorbidities, including osteoporosis, are increasing. Fracture risk is higher and increases...
9.
Kusejko K, Marzel A, Hampel B, Bachmann N, Nguyen H, Fehr J, et al.
HIV Med
. 2018 Jul;
19(10):688-697.
PMID: 30051600
Objectives: Despite the huge success of antiretroviral therapy (ART), there is an ongoing HIV epidemic among men who have sex with men (MSM) in resource-rich countries. Understanding the driving factors...
10.
Sculier D, Doco-Lecompte T, Yerly S, Metzner K, Decosterd L, Calmy A
HIV Med
. 2018 Jun;
PMID: 29932298
Objectives: Dolutegravir (DTG) is a highly effective integrase inhibitor with a strong genetic resistance barrier and a potential role in simplified HIV maintenance treatment. We assessed the feasibility of DTG...